A substantial proportion of the broadly neutralizing antibodies (bnAbs) identified in certain HIV-infected donors recognize glycan-dependent epitopes on HIV-1 gp120. Here we elucidate how the bnAb PGT 135 binds its Asn332 glycan-dependent epitope from its 3.1-Å crystal structure with gp120, CD4 and Fab 17b. PGT 135 interacts with glycans at Asn332, Asn392 and Asn386, using long CDR loops H1 and H3 to penetrate the glycan shield and access the gp120 protein surface. EM reveals that PGT 135 can accommodate the conformational and chemical diversity of gp120 glycans by altering its angle of engagement. Combined structural studies of PGT 135, PGT 128 and 2G12 show that this Asn332-dependent antigenic region is highly accessible and much more extensive than initially appreciated, which allows for multiple binding modes and varied angles of approach; thereby it represents a supersite of vulnerability for antibody neutralization. npg
a r t i c l e s The human immune system initially generates strain-specific neutralizing antibodies to HIV-1 that recognize only a fraction of the massively diverse mutational variants of its envelope glycoprotein (Env) 1 . In the infected host, the virus diversifies extensively and escapes from these narrowly focused antibodies. Strong selection pressure drives variation in its exposed surfaces, including its five hypervariable loops (V1-V5) and ~27 N-linked glycans that cover most of the gp120 envelope-glycoprotein surface [2] [3] [4] . Despite this extraordinary sequence variation and the 'evolving glycan shield' , broadly neutralizing activity is found in 5-25% of donor sera after 2-3 years of infection 5, 6 . However, by that time, the virus has firmly established itself, overwhelming even broadly neutralizing responses. Nevertheless, elicitation of such responses by a vaccine before virus exposure may lead to prophylactic protection against HIV-1.
Given that neutralizing-antibody selection pressure shifts glycosylation sites on the virus during the course of infection 2 , it is reasonable to assume that these antibodies may be targeting not only protein surfaces near glycans but also the glycans themselves. This notion is supported by observations of serum neutralizing activity that is dependent on the presence of the glycan attached to Asn332 (refs. 7-10) and by the recent discovery of several bnAbs that interact with Env in a glycan-dependent manner. Four antibodies isolated from different HIV-1-infected donors and derived from different germline families, PGT 121 (ref. 11 ), 2G12 (ref. 12) , PGT 128 (ref. 13 ) and PG9 (ref. 14) , have been structurally characterized in complex with a complex glycan, high-mannose glycans, a gp120 outer-domain fragment and a scaffolded glycopeptide, respectively. A number of other glycan-dependent bnAbs, including PG16, PGTs 121-123, PGTs 130-131, and PGTs 142-145 (grouped according to their predicted shared germline precursor) await structural characterization in complex with Env 15, 16 .
To further elucidate the bnAb target around Asn332, we conducted structural and functional analysis of PGT 135, an Asn332 glycandependent bnAb isolated from an individual whose serum has one of the highest neutralization breadths known 16, 17 . The PGT 135 epitope includes three glycans and protein segments that differ substantially from other Asn332-dependent epitopes and enable PGT 135 accommodation of HIV-1 Env-glycan heterogeneity through some variation in its a r t i c l e s angle of approach to the gp120 surface. Hence, the Asn332-dependent epitope constitutes a major site of vulnerability on the glycosylated face of gp120 that can be accessed by antibodies from different germline precursors, using completely different modes of recognition and, most probably, different mechanisms of neutralization.
RESULTS

Structural characterization of PGT 135 binding to gp120
To elucidate the interaction with gp120, we tested PGT 135 Fab complexed with a number of gp120 core constructs and additional ligands for crystallization. The additional ligands included soluble CD4 receptor and Fabs recognizing gp120 to increase the chances of crystallization 18 . Crystals of a quaternary complex (that is, with four protein components) consisting of PGT 135 Fab, JR-FL core gp120, CD4 D1D2 domain and 17b Fab ( Fig. 1) diffracted to 3.1-Å resolution ( Table 1) , whereas ligand-free Fab135 crystals diffracted to 1.75 Å ( Table 1) . The JR-FL gp120 monomeric core bound PGT 135 Fab with high affinity (82 nM by isothermal titration calorimetry (ITC) Supplementary  Table 1 ), but the corresponding virus was only weakly neutralized by PGT 135 IgG unless specific mutations were introduced into the V1-V2 loops, which are >25 Å away from the epitope in the monomeric gp120 structure and probably affect binding indirectly by affecting trimer interactions (Fig. 2) 19 . Nevertheless, the weak neutralization that we observed correlates with an approximate micromolar binding affinity for the Env trimer. A number of bnAb-Env complexes in this affinity range have been structurally elucidated, for example, b12 with a stabilized gp120 core construct 20 and PG9 with V1-V2-loop scaffolds 14 , and these structures are consistent with many published findings on Env biology.
The crystal structure shows that CD4, 17b and PGT 135 are bound to gp120 in nearly orthogonal orientations ( Fig. 1a) . After partially deglycosylating the gp120-PGT 135 complex by endoglycosidase H (EndoH) before crystallization, we observed only single N-acetylglucosamine (GlcNAc) moieties in the gp120 electron density at Asn339, Asn362, Asn448, Asn262 and Asn276, whereas the highmannose (Man) glycans interacting with PGT 135 were protected; electron density was visible for GlcNAc 2 Man at Asn386, GlcNAc 2 Man 6 at Asn332 and GlcNAc 2 Man 8 at Asn392. As compared to its ligand-free structure, PGT 135 does not undergo any large conformational changes (0.4-Å Cα r.m.s. deviation between Fab variable domains; Supplementary Fig. 1a,b) . The gp120 JR-FL structure is also highly similar to that in the gp120 HXBC -CD4-17b complex 20 (0.5-Å Cα r.m.s. deviation), suggesting that PGT 135 does not induce any further conformational changes when it binds gp120. This inference was corroborated by ITC data: the ∆G, ∆H and T∆S values for PGT 135 binding ligand-free gp120 and for the a b Figure 1 Crystal structure of PGT 135 in complex with HIV-1 gp120 core. (a) The glycandependent interaction between PGT 135 and gp120, presented in ribbon representation in the context of the gp120 ternary complex that contains a two-domain CD4 and the Fab of CD4-induced antibody 17b. An enlarged display of the PGT 135-gp120 interaction is shown to the lower right. The CDR H1 and H3 loops (dark blue and red, respectively) on the heavy chain (HC) penetrate deeply through the glycan canopy to contact protein surface below while the light chain (LC) contacts the glycans by using CDR loops and framework regions. (b) Buried surface on gp120 protein surface and attached glycans at Asn332, Asn386 and Asn392 by CDR loops and framework regions of PGT 135 (values in Å 2 ). npg gp120-CD4 complex were nearly equivalent ( Supplementary Table 1 ). Therefore, evidence that PGT 135 neutralizes virus by inducing conformational changes in gp120 or by direct inhibition of CD4 binding is lacking. However, the PGT135 neutralization mechanism still remains unclear, although we note that the PGT 135 epitope also involves residues from the V4 loop. In another study, an anti-Flag antibody, which neutralizes recombinant virus containing a Flag insert in the V4 loop 21 , appears to function by nonspecific steric coverage of the virion 22 instead of by blocking functionally important surfaces such as the CD4-binding site.
PGT 135 engages gp120 primarily through a long 18-residue complementarity-determining region (CDR) H3 loop, which has an insertion of ten amino acids (aa) after position 100 (the average human CDR H3 is 13 residues, using the Kabat definition of H95-H102 (ref. 23)) and an extended CDR H1 loop containing a rare 5-aa insertion not present in the predicted germline sequence ( Supplementary Fig. 2) ; both CDR loops protrude approximately 20 Å from the surface of the heavy-chain variable region (V H ) which is comparable to the length of high-mannose N-linked glycans. The V H CDR loops in ligandfree PGT 135 converge to form a highly hydrophobic horseshoeshaped surface consisting of Trp34 from CDR H1, Trp53 from H2 and Val100-Phe100A-Met100B-Leu100C-Val100D-Pro100E-Ile100F (in the Kabat numbering system) from H3 ( Supplementary Fig. 1d ). A salt bridge between Arg54 on the tip of H2 and Glu33 near the top of the H1 loop insertion helps to hold these loops in place. These features remain intact after gp120 binding ( Supplementary Fig. 1c ).
The PGT 135 interaction with gp120 defines a complex epitope that consists of 438 Å 2 of protein and 1,010 Å 2 of glycan surface on gp120 ( Fig. 1 and Supplementary Table 2 ), which is larger than the typical antibody footprint (of ~700-900 Å 2 ). Eighty-three percent of the protein-protein buried surface involves side chains on gp120 ( Supplementary Table 2 ), in contrast to PG9 and PGT 128, which rely primarily on backbone interactions with V1-V2 and V3, respectively, to form main chain β-strand associations 13, 14 . The CDR H1 and H3 tips primarily contact gp120 β-strand 19, which connects the V4 loop to β-strand 20, as part of the bridging sheet ( Fig. 1b) , and adjacent β-strand 13, between V3 and α-helix 2, where His330 is particularly important for binding and neutralization ( Supplementary Tables 2 and 3 ). On the gp120 V4 loop, Glu409 interacts with CDRs L2 and H3, forming a protein-protein interaction zone that is discontinuous from the rest of the contacts. The CDR H1 insertion allows access to the protein surface around the Asn386 glycan (GlcNAc 2 Man), which separates the PGT 135 epitope from the CD4-binding site. Trp34 on the tip of the CDR H1 insertion interacts with the Asn386 glycan. Additionally, bnAb b12 contacts residues near the Asn386 glycan through CDR H3 Trp100, which occupies a similar position to PGT 135 H1 Trp34 (ref. 20) . Deletion of the H1 insertion abolishes PGT 135 neutralization of different HIV-1 isolates (Fig. 2b,c) , which suggests that this extended loop is important for the antibody-antigen interaction.
The large glycan-binding surface of PGT 135 is created by the CDR loops draping themselves across the entire length of the N-linked glycans at Asn392 (547 Å 2 ) and Asn332 (365 Å 2 ), in which multiple van der Waals interactions and hydrogen bonds are made from the mannose sugars at the tips of the D2 and D3 arms to the GlcNAc moieties at the stem proximal to the asparagine (Figs. 1  and 3 and Supplementary Tables 2 and 4-7) . The Asn386 glycan interaction is significantly less (99 Å 2 ; two van der Waals interactions with H1) than those of the Asn392 and Asn332 glycans but is nonetheless critical for neutralization of various HIV-1 strains ( Fig. 3d and Supplementary Tables 3-7) . Notably, the Asn392 and Asn332 glycans interact with opposite faces of PGT 135 CDR H3 in a bifurcated manner reminiscent of bnAb PG9 and PGT 128 binding to dual glycans on epitope-scaffolded V1-V2 loops (PG9) or gp120 outer domain (PGT 128), respectively ( Fig. 3a) . However, unlike the case in these other bnAbs, whose interacting glycans are on adjacent β-strands, the two glycans interacting with PGT 135 CDR H3 are on independent β-strands separated by β-strand 19 (Fig. 1) . The light-chain variable region (V L ) also contacts the Asn332 glycan through CDR L3 on one side of V L , whereas CDR L2 and V L framework regions 2 and 3 on the opposite side interact with the Asn392 glycan ( Fig. 1) .
Glycan specificity of PGT 135
N-linked glycans exhibit multiple levels of heterogeneity arising from variable positioning of the glycosylation sequons on gp120, npg a r t i c l e s differential processing by Golgi enzymes and conformational flexibility 24, 25 . To understand how PGT 135 achieves relatively broad neutralizing activity despite dependence on heterogeneous glycans, we used virus neutralization and binding assays of virus and gp120s from different strains with various N-linked-glycosylation knockouts, along with glycan arrays and different expression systems ( Fig. 3b-d) . These results were compared with analysis of the glycans in the crystal structure of a partially deglycosylated PGT 135 complex. Crystallization required partial deglycosylation of the complex, which we carried out with the rationale that EndoH will preferentially cleave the more exposed and flexible N-linked glycans 26 that are not protected by PGT 135 binding ( Supplementary Fig. 3d ).
Pseudoviruses prepared from mammalian HEK293T cells (with complex, hybrid and oligomannose glycans) or HEK293S cells (with Man 5-9 GlcNAc 2 oligomannose glycans) had similar PGT 135 neutralization profiles (Fig. 3c) . These results are consistent with the crystal structure, which shows interaction only with an oligomannose glycan patch on gp120 (ref. 27 ) that would be present when gp120 is expressed in either cell line, and they validate the use of HEK293S cells to produce the gp120 for the crystal study. In contrast to 2G12 and PGT 128, PGT 135 also neutralized pseudoviruses from cells treated with both kifunensine and N-butyldeoxynojirimycin (NB-DNJ), which results in either missing or glucosylated (masked) D1 arms of N-linked glycans 28 . This observation is also consistent with the crystal structure because PGT 135 does not interact with the Asn332 glycan D1 arm and interacts only with the second mannose residue of the Asn392 glycan D1 arm, which would not be affected by NB-DNJ treatment (Fig. 3a) . Also in contrast to 2G12 and PGT 128, adding only kifunensine to the expression system, which limits glycan processing to Man 9 GlcNAc 2 , resulted in loss of neutralization by PGT 135. Again, the crystal structure is compatible with this outcome: modeling an additional mannose residue to the D2 arm of the Man 8 glycan at Asn392 would result in a severe steric clash (Supplementary Fig. 3a) . The D2 arm of the Man 6 glycan at Asn332 is also sterically crowded, but it may be able to accommodate a terminal mannose with some slight adjustment ( Supplementary  Fig. 3b ). In contrast, the D3 arm of the Asn332 glycan is free from any steric clash with the antibody (Supplementary Fig. 3c ).
Glycan array binding assays showed that PGT 135 recognized Man 7-9 glycans exclusively and bound these with lower affinity than did 2G12 and PGT128 (Fig. 3b) . Although PGT 135 appears to bury extended glycan moieties in the binding site, most of the contacts are van der Waals interactions, and the antibody makes only four hydrogen bonds to the Asn332 glycan. In contrast, PGT 128, which generated a substantially higher glycan binding signal on glycan arrays, makes 13 hydrogen bonds with the Asn332 glycan. The pattern of binding to these glycans is dependent on the density, clustering and conformation of the presented glycans; in a different glycan array format using noncovalently immobilized N-linked glycans as neoglycolipids that have an element of mobility, only Man 8 and Man 7 glycans without the terminal D2 mannose were recognized (Supplementary Table 8 ). The array analyses and kifunensine effect described above can be reconciled if binding to glycans other than Asn392, probably to Asn332, could occur through Man 8 or Man 9 . Although a homogeneous display of glycans on an array is unlikely to mimic the actual presentation of the glycans on gp120, the use of multiple arrays containing different immobilization methods and printing densities allows more opportunity for assessment of the glycan specificity of PGT 135.
Virus neutralization and binding assays revealed differential effects of these N-linked glycosylation sites on PGT 135 activity against npg a r t i c l e s different isolates of HIV-1 (Fig. 3d) . Not surprisingly, Asn332 and Asn392 were required for all isolates tested because most of the antibody contacts are to these glycans. However, the requirement for Asn295 and Asn386 glycans, as well as the His330 residue, on gp120 was strain dependent. Although the Asn295 glycan does not contact PGT 135 in the context of the JR-FL core gp120, these data suggest that it may be recruited by the antibody in the context of other HIV-1 strains so that the epitope would be modified and strain dependent. Thus, although the PGT 135 interaction is highly specific for particular glycoforms on gp120, it may also be promiscuous by exploiting a neighboring Asn295 glycan for recognition of some HIV-1 strains. By targeting the oligomannose patch on gp120 where the required glycoforms are present, while tolerating a certain range of alternate glycan positions, PGT 135 may acquire broad neutralizing breadth despite the heterogeneity seen in the Env-glycan populations. Overall, the data point toward two general requirements for PGT 135 binding, with the caveat that any given isolate may deviate from the most common pattern of recognition: (i) high-mannose glycans within the context of the tightly clustered high-mannose patch on gp120 and (ii) a D2 arm on the glycan at Asn392 lacking at least the terminal mannose residue.
Structural explanation for neutralization breadth of PGT 135
PGT 135 can neutralize 33% of HIV-1 isolates at a half-maximal inhibitory concentration (IC 50 ) <50 µg ml −1 in a 162-cross-clade virus panel, which is comparable to neutralization by bnAb b12 (34%), but less than by PGT 128 (72%) 7 , although PGT 135 and PGT 128 both recognize epitopes critically dependent upon the same highly conserved Asn332 glycan 7 . The variability of important residues and glycan sites was examined by using 3,045 aligned gp120 sequences (Los Alamos HIV Database). The sequence conservation of the essential elements necessary for gp120 binding agrees well with neutralization breadth ( Supplementary Table 2 ). For PGT 128, glycans at Asn332 (73% conserved) and Asn301 (92% conserved) are critical for neutralization; both glycan motifs are present together in 69% of the sequences, which is close to the observed 72% neutralization breadth 7 . For PGT 135, glycans at Asn332, Asn392, Asn295, Asn386 and His330 (73%, 79%, 59%, 87% and 71% conserved, respectively) are all important for neutralization ( Supplementary Table 2 ). His330, Asn332 and Asn392 are all required for neutralization of all isolates tested (Fig. 3d) , and these three sites are found concurrently in 50% of the sequences. However, PGT 135 recognition also requires Asn295 and Asn386 glycans in a strain-dependent manner. His330 and glycans at Asn332, Asn392 and either Asn295 or Asn386 are found in 31% or 42% of the sequences, whereas His330 along with all four glycan motifs (at aa 332, 392, 295 and 386) is present in 26% of the sequences. The observed neutralization breadth of PGT 135 is 33% of test isolates 7 , which suggests that the dispensability of either Asn295 or the Asn386 glycans in certain strains enhances neutralization breadth compared to that when all four glycans and His330 are required.
PGT 135 interaction with a gp140 trimer construct
We used EM to characterize PGT 135 Fab binding to a glycosylated clade A BG505 SOSIP.664 gp140 trimer 29 . Three Fabs were bound per trimer, with the gp120 protomers in a more closed conformation ( Fig. 4a ) than that seen with CD4-binding-site ligands 30 . The PGT 135 angle of approach to the gp120 epitope avoids any clash with neighboring gp120 protomers or interference with the CD4-binding site (Fig. 4a) . The 2D class averages showed that PGT 135 occupies a distinct epitope from that of PGT 128, which also recognizes the Asn332 glycan (Fig. 4b) , but we observed marked variance in the orientation of Fab PGT 135 relative to the trimer ( Fig. 4c and Supplementary  Movie 1) . Principal component analysis (PCA) of the variance clearly illustrated some flexibility in the Fab PGT 135 interaction with the trimer compared to that of PGT 128 ( Fig. 4d and Supplementary Movie 2) . This increased variance for PGT 135 may represent a distribution of different angles of approach, owing to some slight shift between the interacting glycans or in the glycoforms it contacts (Fig. 4d) . The use of alternative angles of approach may therefore reflect an immunologic countermeasure to some natural variation in the N-linked glycans that decorate the Env surfaces of different HIV-1 isolates. a r t i c l e s responses can be made against the glycosylated face of gp120, particularly around the Asn332 glycan. PGT 135, 2G12 and PGT 128 bnAbs are all dependent on the Asn332 glycan but have distinct binding motifs and quite different angles of approach (Fig. 5a) , and yet their neutralization activity is not compromised. This scenario contrasts with antibodies whose binding footprints overlap the CD4-binding site, where small differences in angle and relative position result in clashes with neighboring gp120s 31 in the Env trimer and very different extents of neutralization from VRC01 (bnAb, 93% breadth) to F105 (non-neutralizing) 5 . Thus, these Asn332-dependent antibodies define a new and unexpectedly broad supersite for neutralization ( Fig. 5b) , which encompasses six conserved glycans and the underlying protein surface. Overall, in comparing HIV-1 bnAbs with known structures that interact with glycans, PGT 135 is similar to PGT 128 and PG9 in its use of heavy-chain CDR loops to penetrate the glycan canopy and contact the underlying protein surface, but PG9 uniquely uses a hammerhead-shaped CDR H3 loop for the interaction. As with PGT 128, but not PG9, PGT 135 relies on a second extended CDR loop on the heavy chain (H1 in PGT 135 and H2 in PGT 128) to contact antigen. Despite their different amino acid lengths, these extended CDR loops are at similar distances from the antibody (15-20 Å), which reflects the length of an N-linked glycan from the underlying protein surface. In contrast, 2G12 contacts only the outermost mannose residues of the interacting glycans, a feature that presumably results from its unusual V H domain swap to attain high-affinity binding.
DISCUSSION
In terms of the relative glycan positioning within the binding sites, we also observe some similarities. For Fabs PGT 135, PGT 128 and 2G12, the distances between the two major interacting glycans on the gp120 surface (measured between the asparagine-bound carbons of the protein-proximal GlcNAcs of the glycans) are remarkably similar, at around 18-20 Å. The PG9 glycans are also spaced similarly, at 15 Å. These similarities in distances are likely to reflect constraints imposed by the dimensions of the Fab-interacting surfaces, the requirement that a CDR loop penetrate between glycans and the density of the glycans on the gp120 surface.
Although three different bnAbs recognize the same Asn332 glycan, they contact chemically distinct surrounding surfaces. The 2G12 antibody binds the glycan tips and is, therefore, highly dependent on the presence of the terminal mannose residues in a particular linkage. In contrast, PGT 135 and PGT 128 recognize the complete length of the glycan at Asn332, but they approach from and interact with different sides of the glycan. Notably, the glycan conformation and orientation is largely unchanged in the PGT 135 and PGT 128 structures (Fig. 6a) , despite the known conformational flexibility of glycans. This conformational stability confers the carbohydrate with two chemically distinct 'faces' at the level of the entire glycan; a much more flexible glycan would not have such well-defined faces because its overall orientation and conformation would be rapidly changing. The Asn332 glycan faces are defined by the sum of the contributions from the apolar and polar faces of individual sugar rings that then determine the net polarity of the complete face. The sugar hydroxyl groups extend from the polar a r t i c l e s side of a sugar ring, thereby potentially mediating more hydrophilictype interactions relative to the apolar face ( Fig. 6b) . Thus, some 'rules' for interaction with individual sugars have been established whereby aromatic residues, such as tryptophan, typically stack on the apolar faces of sugars, and hydrophilic and charged residues interact with the polar faces and hydrogen-bond with the ring hydroxyl groups 32 . We observed that PGT 135 interacts predominantly with an apolar face consisting of three individual apolar sugar-ring faces and one polar sugar-ring face (Fig. 6c) , with 61% of the buried surface in the interaction mediated by the individual apolar faces. PGT 128 interacts with a predominantly polar face consisting of five individual polar sugar faces and two individual apolar sugar ring faces, with 58% of the buried surface mediated by the polar faces (Fig. 6d) . Conversely, PGT 135 residues interacting with the apolar face of glycan 332 are predominantly hydrophobic (with ~64% of the buried-surface-area contacts mediated by apolar residues), whereas PGT 128 residues are about equally hydrophobic and hydrophilic (with ~54% of the buried surface in the interaction mediated by apolar residues). Some of the interactions with each antibody are with the sides of the sugar rings rather than with the faces (Fig. 6c,d) . Of note, the apolar interactions, particularly ring stacking, would naturally involve much greater surface area than would hydrophilic interactions. Similarly, PGT 128 interactions with the polar face of glycan 332 involve many more hydrogen bonds than those of PGT 135 (13 versus 4). Thus, we conclude that the different faces of the Asn332 glycan are an important determinant for antibody recognition of this supersite.
The discovery of bnAbs, in a simian-human immunodeficiency virus-infected macaque, that depend on the Asn332 glycan, in addition to those described above in infected humans [7] [8] [9] , raises the prospect that suitable immunogens that display these combined glycan and protein epitopes in an appropriate configuration could be tested as vaccine candidates in animal models for re-elicitation of similar glycan-dependent antibodies. Furthermore, a recent study showed that broadly neutralizing responses were raised against the Asn332 glycan in two human individuals infected with a virus initially lacking the Asn332 glycan but containing an Asn334 glycan that is present only when Asn332 is absent 9 . The Asn332 glycan emerges later in the infection, but the virus can revert back to the Asn334 glycan, which results in escape from the immune response. Although most viruses have the Asn332 glycan (73%) rather than the Asn334 glycan (20% conserved), a vaccine may need to be capable of inducing responses to either glycan site.
It is still not clear why the Asn332 glycan is so dominant among antibodies targeting this supersite, but one possibility is that it not only is highly conserved (73%) and predominantly oligomannose but also is conformationally restrained by adjacent sugars. Indeed, the glycan Asn332 conformation is nearly identical in the crystal structures of PGT 128 (ref. 13 ) and PGT 135 ( Fig. 6) , which suggests that the immune system is presented with a comparatively well-ordered sector of the glycan shield, at least for glycan Asn332. Heterogeneity of surrounding glycans may be accommodated, as suggested by the distribution of angles of approach used by PGT 135 and by PGT 121's potential ability to bind both high-mannose and complex glycans 11 . One implication for vaccine design is that immunization with an antigen containing a heterogeneous mix of glycoforms and glycosylation sites may promote 'promiscuous' antibodies that have greater neutralization breadth. However, this benefit may be countered by a dampened immune response, in which case different vaccination schedules and adjuvants would need to be tested. Ultimately, mimicking this supersite by using rational vaccine design, such as epitope scaffolding 33, 34 , to create vaccine immunogens should require careful consideration of how to produce a faithful representation of the glycan canopy with glycoforms that are similar to those in the intact Env trimer.
METHODS
Methods and any associated references are available in the online version of the paper. Accession codes. Coordinates and structure factors for Fab PGT 135 and its complex with gp120, CD4 and 17b have been deposited in the Protein Data Bank under accession codes 4JM4 and 4JM2, respectively. The Fab PGT 135-SOSIP.664 trimer EM reconstruction density has been deposited in the Electron Microscopy Data Bank under accession code EMD-2331. 
ONLINE METHODS
Expression and purification of PGT 135 and 17b Fab. PGT 135 Fab was expressed by using a baculovirus system with SF9 cells as described previously 13 . PGT 135 was purified from the cell supernatant first by anti-human lambda affinity chromatography followed by cation-exchange chromatography and sizeexclusion chromatography using Superdex 200 (GE Healthcare), as previously described 13 . Fab 17b was obtained from digesting IgG 17b with papain by using a previously described protocol 12 .
Expression and purification of JR-FL gp120 core. A JR-FL gp120 core containing a short (mini) V3 region (residues 305-320 deleted and replaced by a proline residue as described in ref. 13 ) was cloned into a phCMV3 vector with an IgK secretion signal. This plasmid was used to transfect HEK293S GnT1 − (293S) cells by using 293Fectin (Invitrogen) under serum-free conditions. The protein was purified first through a Galanthus nivalis lectin column, followed by SEC with Superdex 200 (GE Healthcare).
Expression and purification of BG505 SOSIP.664 trimer. The HIV-1 clade A BG505 Env sequence and the construction of SOSIP.664 trimers 35 by using the Env sequence of BG505.W6M.ENV.C2 (GenBank accession ABA61516/ DQ208458) designed with a T332N mutation 36 was described previously 29 . The BG505 SOSIP.664 trimer was expressed and purified as previously described 13 . The BG505 SOSIP.664 trimer was purified by a 2G12-coupled affinity matrix followed by passage through a sizing column.
Crystallization and data collection. Ligand-free PGT 135 Fab crystallized over a period of 28 days at 20 °C in a crystallization reagent consisting of 20% (w/v) PEG 8000 and 0.1 M CHES, pH 9.5. Crystals were harvested and cryoprotected by a brief immersion in 70% well buffer, 30% glycerol, followed by immediate flash-cooling in liquid nitrogen. Data were collected at APS beamline 23ID-B (wavelength 1.033 Å) at 100 K. Data were processed and scaled with HKL-2000 (ref. 37) . Quaternary complexes of PGT 135 crystallized in 20% PEG 2000, 0.1 M Tris, pH 7.0 (JCSG CoreSuite I Well C07), with the JCSG/IAVI/TSRI automated CrystalMation robotic system (Rigaku). An optimization screen was made around this condition, and large single crystals were obtained from 16% w/v PEG MME 2000 and Tris, pH 7.87, by using the Oryx8 Crystallization robot. Data were collected at the ALS beamline 5.0.2 (wavelength 1.000 Å) at 100 K and were processed and scaled with HKL-2000 (ref. 37) . All data processing statistics are summarized in Table 1 .
Structure determination and refinement. The ligand-free PGT 135 structure was determined with the molecular replacement method by using Phaser with an unrelated Fab structure (PDB 3KYM) as an initial model. For the quaternary complex, multiple components were used for phasing: 17b Fab (PDB 2NXY), soluble CD4 (PDB 2NXY), gp120 core (PDB 2NXY) and high-resolution ligandfree PGT 135 Fab as determined here. Model building was carried out by using Coot-0.6.2, and refinement was implemented with Phenix 38 . Supplementary Note gives refinement details, Supplementary Figure 4 shows glycan geometry validation, and Table 1 gives final refinement statistics.
Isothermal titration calorimetry. Isothermal titration calorimetry (ITC) binding experiments were performed by using a MicroCal iTC200 instrument (GE). Details are in Supplementary Note. gp120 binding ELISAs. Recombinant gp120 (250 ng) was immobilized directly onto flat-bottom microtiter plates (Costar type 3690, Corning) at 4 °C overnight. Antibody binding was determined as described above. Fold change in binding for PGT 135 mutants is summarized in Supplementary Table 9 .
Generation of pseudovirus. Pseudovirus was generated in HEK293T or GnT1 − HEK293S cells as described previously 39 . Glycosidase inhibitors were added at the time of transfection and were used alone or in combination at the following concentrations as described in ref. 13 : 25 µM kifunensine and 2 mM N-butyldeoxynojirimycin (NB-DNJ).
Neutralization assays. Neutralization activity of antibodies to pseudovirus in TZM-bl cells was determined as described previously 39 . Fold change in neutralization for PGT 135 mutants is summarized in Supplementary Table 10 .
Antibody and envelope mutations. Mutations in the PGT heavy chain, the HIV-1 envelope glycoprotein and the JR-FLmV3 construct were introduced by using QuikChange site-directed mutagenesis (Stratagene). Mutations were verified by DNA sequencing (Eton Biosciences).
JR-FLmV3 glycan mutant binding ELISAs. JR-FLmV3 glycan mutants were expressed in HEK293S cells. Glycoproteins from the crude supernatant were captured on ELISA plates by using mAb 17b. Serial dilutions of biotinylated PGT 135 were added, and antibody binding was probed with alkaline phosphatase-conjugated streptavidin (Jackson; diluted to 1:1,000) and visualized with p-nitrophenol phosphate substrate (Sigma) at 405 nm.
High-density high-mannose array printing. Man 7 GlcNAc 2 -Gly, Man 8 GlcNAc 2 -Gly and Man 9 GlcNAc 2 -Gly were printed in replicates of six onto NHS-activated glass slides (ADA Technologies) at a concentration of 100 µM as previously described 13 by using a MicroGridII contact microarray printing robot. Printing efficiency was determined by measuring ConA binding.
Binding of antibodies to high-density high-mannose array. Binding of PGT 135, PGT 128 and 2G12 antibodies was measured at 30 µg/ml and detected by using goat anti-human Fcγ-R-PE at 1:66.7 dilution (15 µg/ml, Jackson Arrays, cat. no. 109-115-098) were scanned for R-PE fluorescence on a ProScanArray HT (PerkinElmer) confocal slide scanner at 70PMT90LP. Signal intensities were collected by using Imagene (BioDiscovery) image analysis software and calculated by using the mean intensity of four replicate spotted samples.
Comparison of PGT 135 binding to low-density (Schott slides) and highdensity (ADA slides) glycan microarrays.
Glycan microarray analysis was initially carried out on high-mannose glycans printed on NHS-activated slides obtained from Schott as in ref. 13 , but binding of PGT 135 could not be detected (Supplementary Fig. 5a ). However, PGT 135 glycan binding could be detected (Supplementary Fig. 5a ) by using the glycan array imprinted on higherdensity NHS-activated slides from ADA Technologies. As a comparison, we show that binding of PGT 128 was greatly enhanced by using the high-density slides (Supplementary Fig. 5b) , and strong binding on the array could still be detected at 1 µg/ml. Neoglycolipid microarray analyses. Analysis with neoglycolipid arrays was carried out as described previously 13 . PGT 135 was precomplexed with biotinylated anti-human IgG (Vector) at a 1:3 ratio (w/w) before application onto the slides at a final concentration of 10 µg/ml. Binding was detected with Alexa Fluor 647-labeled streptavidin (Molecular Probes) at 1 µg/ml. Included for comparison are the results with human 2G12 (Polymun Scientific) taken from an earlier experiment performed by using a different version of microarrays 40 , PGT128 and plant lectin ConA in ref. 13 ( Supplementary Table 8 and Supplementary Fig. 5c ).
Electron microscopy and image processing. PGT 135 Fab in complex with the BG505 SOSIP.664 trimer used for EM studies were prepared as previously described 13 . Particles were picked automatically by using DoG Picker and put into a particle stack by using the Appion software package 41, 42 . Initial referencefree 2D class averages were calculated by using particles binned by 4 with Xmipp Clustering 2D Alignment 43 and IMAGIC 44 . Particles were further classified into reference-free 2D class averages and refined by using Refine2d in the EMAN package 45 (Supplementary Fig. 6a ). An ab initio 3D model was generated by refining the EM map of a ligand-free BG505 SOSIP.664 trimer for 29 iterations against the 2D class averages from the last Refine2d iterations. This initial model was used for the final 75-iteration 3D refinement against 8,831 raw particles binned by 2 by using EMAN 45 . C3 symmetry was imposed throughout the reconstruction process. The final 3D reconstruction has a resolution of 20 Å by an FSC cutoff at 0.5 (Supplementary Fig. 6b ).
Fitting of gp120-PGT 135 crystal structure into the EM density. Owing to the high B values in the constant region of the PGT 135 Fab, initial rigid body fitting of the crystal structure was done with only the gp120 and the variable region of the PGT 135 Fab (Supplementary Fig. 6c ). This structure was manually fitted into the EM density and refined by using the UCSF Chimera 'Fit in Map' function. 
